NAVIGATE-ing active surveillance options

Today we focus on the NAVIGATE study, a randomised trial of an online decision aid for men and their partners recently diagnosed with localised prostate cancer. Active surveillance is the preferred option for many men with low-risk prostate cancer, and may also be recommended for some men with favourable intermediate-risk prostate cancer, but many patients find the idea of surveillance to be stressful, and find the choice of management options to be bewildering. So today we chat with some of the team behind the NAVIGATE study which is designed to address some of these issues. NAVIGATE is running in Australia, sponsored by Swinburne University with the trial team based at Peter MacCallum Cancer Centre.
Joining us in studio are Natalie Richards who is a research nurse and NAVIGATE Project Manager, Alan White, patient representative on the project, and via Zoom is Dr Matt Roberts, a urologist in Brisbane who is actively enrolling patients. We also hear from a patient who is actively participating in the study and provides a terrific perspective having been on surveillance initially, and then went on to have surgery when his cancer changed while on surveillance. Your co-hosts are Declan Murphy and Renu Eapen from Peter Mac.
NAVIGATE is 80% recruited and is expected to finish recruitment in 2021. See below for details of how to find out more. Patients may be referred by their clinician or may self-refer directly to the NAVIGATE team if their cancer is suitable for surveillance. The Principal Investigator is Professor Penelope Schofield and the trial is funded by an NHMRC grant.